3-(2,2,2-trimethylhydrazine)propionate has been researched along with Heart Failure in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Cirule, H; Dambrova, M; Kigitovica, D; Korzh, S; Liepinsh, E; Makrecka-Kuka, M; Skride, A; Videja, M; Vilks, K; Vilskersts, R | 1 |
| Fabritskaya, SV; Shilina, NN; Statsenko, S; Turkin, SV | 1 |
| Tsverava, MD | 1 |
| Shilina, NN; Statsenko, ME; Turkina, SV | 1 |
| Maisch, B; Rupp, H; Zarain-Herzberg, A | 1 |
| Bagdonas, G; Kalvinsh, I; Knasene, Iu; Lesaukaite, V; Matsiyauskene, Iu; Visokinskas, A | 1 |
| Iushchuk, EN; Khadzegova, AB; Sadulaeva, IA; Shkol'nik, EL; Vakhromeeva, MN; Vasiuk, IuA; Vit'ko, NK | 1 |
| Belenkova, SV; Shilina, NN; Sporova, OE; Statsenko, ME | 1 |
| Kutuzova, AE; Nedoshivin, AO; Perepech, NB | 1 |
| Kutuzova, AE; Nedoshivin, AO; Perepech, NB; Petrova, NN | 1 |
| Asaka, N; Hayashi, Y; Kirimoto, T; Matsuura, N; Miyake, H; Nakano, M; Tajima, K | 1 |
| Hayashi, Y; Hoshiai, K; Hoshiai, M; Ishida, H; Kanno, T; Kirimoto, T; Matsuura, N; Miyake, H; Nakano, M; Nakazawa, H; Tajima, K | 1 |
| Artiukh, VP; Sakharchuk, II; Sisetskiĭ, AP; Starodub, NF | 1 |
| Artiukh, VP; Denisenko, GT; Sakharchuk, II; Sisetskiĭ, AP; Starodub, NF | 1 |
1 review(s) available for 3-(2,2,2-trimethylhydrazine)propionate and Heart Failure
| Article | Year |
|---|---|
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
Topics: Acetanilides; Angina Pectoris; Animals; Calcium; Cardiovascular Agents; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Methylhydrazines; Myocytes, Cardiac; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Trimetazidine; Up-Regulation; Vasodilator Agents | 2002 |
4 trial(s) available for 3-(2,2,2-trimethylhydrazine)propionate and Heart Failure
| Article | Year |
|---|---|
[Use of meldonium in the combination treatment of patients with heart failure in the early postinfarction period].
Topics: Aged; Cardiovascular Agents; Diastole; Drug Therapy, Combination; Female; Heart Failure; Heart Rate; Humans; Injections, Intravenous; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Systole; Treatment Outcome | 2014 |
[Comparative trial of efficacy of trimethasidine MB and 3-(2,2,2-trimethylhydrasine) propionate dihydrate in chronic heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Chronic Disease; Combined Modality Therapy; Diuretics; Drug Administration Schedule; Female; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Positron-Emission Tomography; Trimetazidine; Vasodilator Agents; Ventricular Dysfunction, Left | 2007 |
[The use of mildronate in combined therapy of postinfarction chronic heart failure in patients with type 2 diabetes mellitus].
Topics: Cardiovascular Agents; Chronic Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Infarction; Prospective Studies | 2007 |
[Mildronate in combined treatment of chronic cardiac insufficiency].
Topics: Cardiac Output; Cardiovascular Agents; Diuretics; Drug Therapy, Combination; Echocardiography; Exercise Tolerance; Follow-Up Studies; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Safety; Treatment Outcome; Vasodilator Agents | 1999 |
9 other study(ies) available for 3-(2,2,2-trimethylhydrazine)propionate and Heart Failure
| Article | Year |
|---|---|
Protective Effects of Meldonium in Experimental Models of Cardiovascular Complications with a Potential Application in COVID-19.
Topics: Animals; Cardiotonic Agents; Cardiotoxicity; COVID-19; COVID-19 Drug Treatment; Disease Models, Animal; Endothelium; Heart Failure; Heart Ventricles; Hydrogen Peroxide; Lung; Male; Methylhydrazines; Mice, Inbred C57BL; Mitochondria; Oxygen Saturation; Rats, Sprague-Dawley; Reactive Oxygen Species; Reperfusion Injury; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right | 2021 |
[Efficacy of Short-Term Therapy With Meldonium in Patients With Chronic Heart Failure of Ischemic Etiology and Type 2 Diabetes Mellitus].
Topics: Aged; Cardiovascular Agents; Chronic Disease; Diabetes Mellitus, Type 2; Female; Heart Failure; Heart Rate; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia | 2017 |
Influence of mildronat on left ventricular systolic, diastolic functional parameters, pulmonary arterial flow and systolic dyssynchrony in patients with congestive heart failure.
Topics: Aged; Echocardiography, Doppler; Female; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Pulmonary Artery; Ventricular Function, Left | 2013 |
[Mildronate in geriatric patients with cardiac failure].
Topics: Age Factors; Aged; Aged, 80 and over; Blood Pressure; Cardiovascular Agents; Female; Follow-Up Studies; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Contraction; Quality of Life; Treatment Outcome | 2006 |
[Effect of mildronate on life quality of patients with chronic heart failure].
Topics: Administration, Oral; Adult; Cardiovascular Agents; Chronic Disease; Female; Heart Failure; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia; Patient Satisfaction; Quality of Life; Stroke Volume; Treatment Outcome | 1999 |
Beneficial effects of MET-88, a gamma-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Body Weight; Cardiovascular Agents; gamma-Butyrobetaine Dioxygenase; Heart Failure; Heart Ventricles; Hemodynamics; Lactic Acid; Male; Methylhydrazines; Mixed Function Oxygenases; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Survival Rate | 2000 |
MET-88, a gamma-butyrobetaine hydroxylase inhibitor, improves cardiac SR Ca2+ uptake activity in rats with congestive heart failure following myocardial infarction.
Topics: Adenine Nucleotides; Animals; Calcium; Captopril; Cardiovascular Agents; Energy Metabolism; Enzyme Inhibitors; gamma-Butyrobetaine Dioxygenase; Heart; Heart Failure; In Vitro Techniques; Male; Methylhydrazines; Mixed Function Oxygenases; Myocardial Infarction; Myocardium; Rats; Rats, Sprague-Dawley; Sarcoplasmic Reticulum | 2000 |
[Erythrocyte functional activity in patients with heart failure and the possible means for its correction].
Topics: Adult; Aged; Cardiovascular Agents; Chronic Disease; Drug Therapy, Combination; Erythrocytes; Heart Failure; Hemodynamics; Humans; Male; Methylhydrazines; Middle Aged; Myocardial Ischemia | 1992 |
[Effects of mildronate on hemoglobin ligand spectrum in patients with ischemic heart disease complicated by coronary insufficiency].
Topics: Aged; Cardiovascular Agents; Coronary Disease; Heart Failure; Hemoglobins; Humans; Ligands; Male; Methemoglobin; Methylhydrazines; Middle Aged; Oxyhemoglobins | 1990 |